

Our Reference: BLA 125611/0

Novo Nordisk Inc.
Attention: Ms. Patricia D. Wilson
May 2, 2017
Sent by email

Dear Ms. Wilson:

We are reviewing your May 16, 2016, biologics license application for Coagulation Factor IX (Recombinant), GlycoPEGylated. We are providing the following comments and request for additional information to continue our review:

1. Determination of polysorbate 80 by (b) (4)

We have the following questions/comments regarding the Method validation report, Document ID 001870476:

- a. You have demonstrated linearity of your assay using the data obtained from polysorbate 80 standards only. Please provide the linearity data based on the analysis of nonacog beta pegol samples, with at least five data points over the proposed assay range.
- b. You have indicated in sections 5.2 and 5.4 that linearity and accuracy were assessed in the range of (b) (4) of polysorbate 80 and (b) (4) of polysorbate 80, respectively. Thus, you have validated your assay in the range of (b) (4) of polysorbate 80. Please explain how this range is relevant to the specification range of (b) (4) of polysorbate 80 in nonacog beta pegol drug product.

2. Determination of sucrose and mannitol contents by (b) (4)

Regarding your Method validation report, Document ID 002197136: You have demonstrated linearity of your assay using the data obtained from reference standards only. Please provide linearity data and plots of analyte concentration vs. peak area to show linearity of sucrose and mannitol response in nonacog beta pegol drug product.

The review of this submission is on-going and issues may be added, expanded upon, or modified.

Please submit your response and your notification of the shipment for this request as an amendment to this file by May 9, 2017, referencing the date of this request. If you

anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is June 3, 2017.

Please send an acknowledgement message for receipt of this request.

If you have any questions, please contact me at (240) 402-8443.

Sincerely,
Edward Thompson
Regulatory Project Manager
FDA/CBER/OTAT/DRPM